Histone deacetylase inhibitors (HDIs) are good anti-cancer targets. Histone acetyltransferases (HATs) and HDIs play opposite roles in the regulation of gene expression via an epigenetic mechanism. HATs catalyse the acetylation of lysine residues in histone tails, facilitating and sustaining gene transcription. HDIs remove the acetyl moieties from the epsilon-amine of lysine residues of histone tails, leading to a more condensed form of chromatin and preventing gene transcription. This book focuses on the use of HDIs for the treatment of lymphoid malignancies; myeloid malignancies; and breast cancer.
Preface; Classification & Function of Histone Deacetylase Inhibitors; Histone Deacetylase Inhibitors in the Treatment of Lymphoid Malignancies; Histone Deacetylase Inhibitors in the Treatment of Myeloid Malignancies; Histone Deacetylase Inhibitors for Breast Cancer:: Driving Out of Stemness; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.